Familial hematological malignancies: ASXL1 gene investigation

Clinical and Translational Oncology

Volumn 18, Issue 4, 2016, Pages 385-390

  Hamadou, W S ^a   Abed, R E ^a   Besbes, S ^a   Bourdon, V ^b   Fabre, A ^b   Youssef, Y B ^a,c   Laatiri, M A ^d   Eisinger, F ^b   Mari, V ^e   Gesta, P ^f   Dreyfus, H ^g   Bonadona, V ^h   Dugast, C ⁱ   Zattara, H ^j   Faivre, L ^k   Jemni, S Y ^c   Noguchi, T ^b   Khelif A ^a,c   Sobol, H ^b   Soua, Z ^a  

^a UNIVERSITY OF SOUSSE   (Tunisia)

^b INSTITUT PAOLI CALMETTES   (France)

^c FARHAT HACHED HOSPITAL   (Tunisia)

^d FATTOUMA BOURGUIBA UNIVERSITY HOSPITAL   (Tunisia)

^e CENTRE ANTOINE LACASSAGNE   (France)

^f CENTRE HOSPITALIER   (France)

^g INSTITUT SAINTE CATHERINE   (France)

^h CENTRE LÉON BÉRARD   (France)

ⁱ CENTRE EUGÈNE MARQUIS   (France)

^j TIMONE HOSPITAL   (France)

^k DIJON UNIVERSITY HOSPITAL   (France)

more..

Author keywords

ASXL1 gene; Familial hematological malignancies; Germline mutation; Non Hodgkin lymphoma

Indexed keywords

ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE MYELOBLASTIC LEUKEMIA; AMINO ACID SUBSTITUTION; ARTICLE; ASXL1 GENE; CHROMOSOME SUBSTITUTION; FEMALE; GENE; GENE AMPLIFICATION; GENE FREQUENCY; GENE SEQUENCE; HEMATOLOGIC MALIGNANCY; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; MYELODYSPLASTIC SYNDROME; NONHODGKIN LYMPHOMA; OPITZ SYNDROME; POLYMERASE CHAIN REACTION; SCORING SYSTEM; SEQUENCE ALIGNMENT; ADULT; AMINO ACID SEQUENCE; CANCER STAGING; DNA MUTATIONAL ANALYSIS; FOLLOW UP; GENETIC PREDISPOSITION; GENETICS; GERMLINE MUTATION; HEMATOLOGIC NEOPLASMS; MISSENSE MUTATION; PEDIGREE; PROGNOSIS; SEQUENCE HOMOLOGY;

ASXL1 PROTEIN, HUMAN; REPRESSOR PROTEIN; TUMOR MARKER;

ADULT; AMINO ACID SEQUENCE; BIOMARKERS, TUMOR; DNA MUTATIONAL ANALYSIS; FEMALE; FOLLOW-UP STUDIES; GENETIC PREDISPOSITION TO DISEASE; GERM-LINE MUTATION; HEMATOLOGIC NEOPLASMS; HUMANS; MALE; MUTATION, MISSENSE; NEOPLASM STAGING; PEDIGREE; PROGNOSIS; REPRESSOR PROTEINS; SEQUENCE HOMOLOGY, AMINO ACID;

EID: 84961136825     PISSN: 1699048X     EISSN: 16993055     Source Type: Journal    
DOI: 10.1007/s12094-015-1379-7     Document Type: Article

References (30)

1. Cho YS, Kim EJ, Park UH, Sin HS, Um SJ. Additional sex comb-like 1 (ASXL1), in cooperation with SRC-1, acts as a ligand-dependent coactivator for retinoic acid receptor. JBC. 2006;281:17588–98.
2. Aravind L, Iyer LM. The HARE-HTH and associated domains: novel modules in the coordination of epigenetic DNA and protein modifications. Cell Cycle. 2012;11:119–31.
3. Lee SW, Cho YS, Na JM, Park UH, Kang M, Kim EJ, et al. ASXL1 represses retinoic acid receptor mediated transcription through associating with HP1 and LSD1. JBC. 2010;285:18–29.
4. Huang HS, Matevossian A, Whittle C, Kim SY, Schumacher A, Baker SP, et al. Prefrontal dysfunction in schizophrenia involves mixed-lineage leukemia 1-regulated histone methylation at GABAergic gene promoters. J Neurosci. 2007;27:11254–62.
5. Ringrose L, Paro R. Polycomb/Trithorax response elements and epigenetic memory of cell identity. Development. 2007;134:223–32.
6. Schwartz YB, Pirrotta V. Polycomb silencing mechanisms and the management of genomic programmes. Nature Rev Genet. 2007;8:9–22.
7. Carbuccia N, Murati A, Trouplin V, Brecqueville M, Adélaïde J, Rey J, et al. Mutations of ASXL1 gene in myeloproliferative neoplasms. Leukemia. 2009;23:2183–6.
8. Gelsi-Boyer V, Trouplin V, Adelaide J, Bonansea J, Cervera N, Carbuccia N, et al. Mutations of polycomb-associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia. Br J Haematol. 2009;145:788–800.
9. Chen TC, Hou HA, Chou WC, Tang JL, Kuo YY, Chen CY, et al. Dynamics of ASXL1 mutation and other associated genetic alterations during disease progression in patients with primary myelodysplastic syndrome. Blood Cancer J. 2014;4:177–85.
10. Hoischen A, van Bon BW, Rodriguez-Santiago B, Gilissen C, Vissers LE, de Vries P, et al. De novo nonsense mutations in ASXL1 cause Bohring-Opitz syndrome. Nature Genet. 2011;43:729–31.
11. Magini P, Della Monica M, Uzielli ML, Mongelli P, Scarselli G, Gambineri E, et al. Two novel patients with Bohring-Opitz syndrome caused by de novo ASXL1 mutations. Am J Med Genet. 2012;158:917–21.
12. Thol F, Friesen I, Damm F, Yun H, Weissinger EM, Krauter J, et al. Prognostic significance of ASXL1 mutations in patients with myelodysplastic syndromes. J Clin Oncol. 2011;29:2499–506.
13. Pratcorona M, Abbas S, Sanders M, Koenders JE, Kavelaars FG, Erpelinck-Verschueren CA, et al. Acquired mutations in ASXL1 in acute myeloid leukemia: prevalence and prognostic value. Hematologica. 2012;97:388–92.
14. Gelsi-Boyer V, Brecqueville M, Devillier R, Murati A, Mozziconacci MJ, Birnbaum D. Mutations in ASXL1 are associated with poor prognosis across the spectrum of malignant myeloid diseases. J Hematol Oncol. 2012;5:12–7.
15. Patnaik MM, Itzykson R, Lasho TL, Kosmider O, Finke CM, Hanson CA, et al. ASXL1 and SETBP1 mutations and their prognostic contribution in chronic myelomonocytic leukemia: a two-center study of 466 patients. Leukemia. 2014;28:2206–12.
16. Abdel-Wahab O, Pardanani A, Patel J, Wadleigh M, Lasho T, Heguy A, et al. Concomitant analysis of EZH2 and ASXL1 mutations in myelofibrosis, chronic myelomonocytic leukemia and blast-phase myeloproliferative neoplasms. Leukemia. 2011;25:1200–2.
17. Quesada V, Conde L, Villamor N, Ordóñez GR, Jares P, Bassaganyas L, et al. Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia. Nature Genet. 2011;44:47–52.
18. Tavtigian SV, Deffenbaugh AM, Yin L, Judkins T, Scholl T, Samollow PB, de Silva D, Thomas A, et al. Comprehensive statistical study of 452 BRCA1 missense substitutions with classification of eight recurrent substitutions as neutral. J Med Genet. 2006;43:295–305.
19. Tong W, Li L, Weng Z. Computational prediction of binding hotspots Conf Proc IEEE. Eng Med Biol Soc. 2004;4:2980–3.
20. Adzhubei IA, Schmidt S, Peshkin L, Ramensky VE, Gerasimova A, Bork P, et al. A method and server for predicting damaging missense mutations. Nat Methods. 2010;7:248–9.
21. Stecher G, Liu L, Sanderford M, Peterson D, Tamura K, Kumar S. MEGA-MD: Molecular Evolutionary Genetics Analysis software with mutational diagnosis of amino acid variation. Bioinformatics. 2014;30:1305–7.
22. Houlston RS, Catovsky D, Yuille MR. Genetic susceptibility to chronic lymphocytic leukemia. Leukemia. 2002;16:1008–14.
23. El Abed R, Bourdon V, Voskoboinik I, Omri H, Youssef YB, Laatiri MA, et al. Molecular study of the perforin gene in familial hematological malignancies. HCCP J. 2011;9:9–16.
24. El Abed R, Bourdon V, Huiart L, Eisinger F, Khelif A, Frenay M, et al. Molecular study of CEPBA in familial hematological malignancies. Fam Cancer. 2009;8:581–4.
25. Su L, Li X, Gao SJ, Yu P, Liu XL, Tan YH, et al. Cytogenetic and genetic mutation features of de novo acute myeloid leukemia in elderly chinese patients. Asian Pac J Cancer Prev. 2014;15:895–8.
26. Katoh M. Functional and cancer genomics of ASXL family members. Br J Cancer. 2013;109:299–306.
27. An Q, Wright SL, Moorman AV, Parker H, Griffiths M, Ross FM, et al. Heterogeneous breakpoints in patients with acute lymphoblastic leukemia and the dic(9;20)(p11-13;q11) show recurrent involvement of genes at 20q11.21. Hematologica. 2009;94:1164–9.
28. Ramanathan A, Mahmoud HAR, Hui LP, Mei NY, Valliappan V, Zain RB. Oral extranodal non Hodgkin’s lymphoma: series of forty two cases in Malaysia. Asian Pac J Cancer Prev. 2014;15:1633–7.
29. Cho YS, Kim EJ, Park UH, Sin HS, Um SJ. Additional sex comb-like1(ASXL1) in cooperation with SRC-1, acts as a ligand-dependent coactivator for retinoic acid receptor. J Biol Chem. 2006;281:17588–98.
30. Tang M, Hou YL, Kang QQ, Chen XY, Duan LQ, Shu J, et al. All-trans-retinoic acid promotes iodine uptake via upregulating the sodium iodide symporter in medullary thyroid cancer stem cells. Asian Pac J Cancer Prev. 2014;15:1859–62.